一种高稳定型泰万菌素肠溶颗粒及其制备方法
Through a core particle design optimized by specific formulation and process, the instability and low bioavailability of tylosin preparations in the gastric acid environment have been solved, achieving high stability and ideal release performance, thus improving therapeutic efficacy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENYANG VICA BIOTECHNOLOGY CO LTD
- Filing Date
- 2025-10-30
- Publication Date
- 2026-07-17
AI Technical Summary
Existing tylosin formulations are unstable in the acidic environment of the stomach, resulting in low bioavailability. Furthermore, existing enteric-coated formulations have complex preparation methods or limited stability improvements, and slow dissolution rates, which affect therapeutic efficacy.
The core particles are designed with a specific formulation, including tylosin tartrate, fillers, disintegrants, lubricants, flow aids and binders, combined with an isolation layer and an enteric coating layer. By optimizing process parameters such as spheroidization, coating temperature and grinding process, a highly efficient porous network and a stable enteric membrane are formed.
It significantly improves the stability and release performance of tylosin in the gastric acid environment, enhances bioavailability, and achieves a clinical cure rate of 80%, which is significantly better than commercially available formulations.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3